Atopic Dermatitis

Featured Article
Examining Available Biologics for Atopic Dermatitis
For the treatment of moderate-to-severe atopic dermatitis, biologics with the most robust efficacy and safety evidence are dupilumab, baricitinib, abrocitinib, and delgocitinib, according to a systematic review.
Study Quantifies High Costs of Prior Authorizations to a Single Dermatology Practice
“Costs likely vary substantially between institutions and practices, but our data suggest that even with an efficient, dedicated prior authorization group, costs are high,” researchers wrote.
Baseline Study Data Shows Substantial Burden of Moderate-to-Severe Atopic Dermatitis
An analysis of the characteristics of 308 adults with moderate-to-severe atopic dermatitis starting or switching systematic therapy provides a real-world picture of the substantial burden of the…

Newsfeed

Examining Available Biologics for Atopic Dermatitis
Study Quantifies High Costs of Prior Authorizations to a Single Dermatology Practice
Baseline Study Data Shows Substantial Burden of Moderate-to-Severe Atopic Dermatitis
Many US Patients Pay $1K or More Out-of-Pocket Annually to Manage Atopic Dermatitis
Unsatisfactory Outcomes Common With Immunosuppressants for Atopic Dermatitis
Discussing Treatment Paradigm Shifts, Successful Therapy Options for Atopic Dermatitis
Early Real-World Data Shows Increased Patient Satisfaction, Demonstrates Effectiveness for AD Therapy
Measuring Real-World Effectiveness of Dupilumab Using IGA Scores to Reduce Symptom Severity
View More

Insights

Discussing Treatment Paradigm Shifts, Successful Therapy Options for Atopic Dermatitis
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients, and…
View More

Interactive Features

Early Real-World Data Shows Increased Patient Satisfaction, Demonstrates Effectiveness for AD Therapy
Measuring Real-World Effectiveness of Dupilumab Using IGA Scores to Reduce Symptom Severity
Weighing Benefits and Challenges to Effectively Treat Atopic Dermatitis
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying patient…
Discussing Effectiveness, Persistence Rates for Atopic Dermatitis Therapy
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues sought to…
View More
Back to Top